We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

105 hedge funds and large institutions have $310M invested in Astria Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less capital invested

Capital invested by funds: $311M → $310M (-$1.55M)

1.37% less ownership

Funds ownership: 103.35% → 101.98% (-1.4%)

9% less funds holding

Funds holding: 115 → 105 (-10)

42% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 24

Holders
105
Holders Change
-10
Holders Change %
-8.7%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
14
Increased
44
Reduced
30
Closed
24
Calls
$35K
Puts
–
Net Calls
+$35K
Net Calls Change
+$66K

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$8.05M
2
Millennium Management
Millennium Management
New York
+$6.47M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.7M
4
NCM
Nantahala Capital Management
Connecticut
+$1.94M
5
VPC
Vestal Point Capital
New York
+$1.66M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$27.3M
2
UBS Group
UBS Group
Switzerland
-$2.58M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.32M
4
ACM
ADAR1 Capital Management
Texas
-$1.9M
5
RG
Redmile Group
California
-$1.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Sio Capital Management
New York
$1.71M +$15.3K +3,151 +1%
Charles Schwab
27
Charles Schwab
California
$1.66M -$21.5K -4,436 -1%
AAA
28
Affinity Asset Advisors
New York
$1.61M +$1.45M +300,000 New
Renaissance Technologies
29
Renaissance Technologies
New York
$1.55M +$536K +110,617 +62%
SFM
30
Sphera Funds Management
Israel
$1.38M +$328K +67,602 +36%
ACM
31
ADAR1 Capital Management
Texas
$1.34M -$1.9M -392,044 -61%
Dimensional Fund Advisors
32
Dimensional Fund Advisors
Texas
$1.18M +$179K +36,830 +20%
Wellington Management Group
33
Wellington Management Group
Massachusetts
$1.04M +$199K +41,138 +27%
Goldman Sachs
34
Goldman Sachs
New York
$950K +$90.8K +18,724 +12%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$674K +$32.5K +6,696 +6%
Barclays
36
Barclays
United Kingdom
$630K +$218K +44,901 +62%
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$555K +$271K +56,006 +118%
Walleye Capital
38
Walleye Capital
New York
$549K +$10.9K +2,242 +2%
TCM
39
Tang Capital Management
California
$536K – – –
PAM
40
Panagora Asset Management
Massachusetts
$528K +$477K +98,458 New
Raymond James Financial
41
Raymond James Financial
Florida
$486K +$59K +12,174 +16%
D.E. Shaw & Co
42
D.E. Shaw & Co
New York
$442K +$308K +63,639 +339%
JF
43
Jump Financial
Illinois
$424K +$222K +45,888 +138%
ECM
44
ExodusPoint Capital Management
New York
$424K +$204K +42,134 +114%
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$410K +$371K +76,554 +123,474%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$406K +$56.5K +11,663 +18%
Jane Street
47
Jane Street
New York
$398K -$168K -34,654 -32%
HSBC Holdings
48
HSBC Holdings
United Kingdom
$335K +$136K +28,043 +85%
AllianceBernstein
49
AllianceBernstein
Tennessee
$311K +$19.1K +3,950 +7%
American Century Companies
50
American Century Companies
Missouri
$303K +$21K +4,335 +8%
1
2
3 4 5

ATXS Hedge Fund Activity: Q2 2025 in Review

105 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2025, worth a combined $310M — down 0.5% from $311M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ATXS and 14 opened new positions — a net loss of 10 holders — while 30 trimmed existing stakes and 44 added.

The largest buyer was JP Morgan Chase, adding an estimated $8.05M. The largest seller was RA Capital Management, exiting entirely with an estimated $27.3M sold.

  • 105 institutional investors held Astria Therapeutics (ATXS) as of Q2 2025, down from 115 in Q1 2025.
  • Funds reported $310M of Astria Therapeutics stock for Q2 2025, down 0.5% quarter-over-quarter.
  • 14 funds opened new Astria Therapeutics positions in Q2 2025 and 24 closed out, a net change of -10 holders.
  • The largest Astria Therapeutics buyer in Q2 2025 was JP Morgan Chase, an estimated $8.05M added.
  • The largest Astria Therapeutics seller in Q2 2025 was RA Capital Management, an estimated $27.3M sold.

Based on aggregated 13F filings for Q2 2025.